Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
A number of other equities research analysts have also weighed in on ICPT. ValuEngine lowered shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, October 8th. Oppenheimer set a $100.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Monday, October 8th. Raymond James lowered shares of Intercept Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and boosted their price objective for the company from $126.00 to $141.00 in a report on Tuesday, October 2nd. They noted that the move was a valuation call. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price objective on shares of Intercept Pharmaceuticals in a report on Monday, October 1st. Finally, Roth Capital started coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, September 12th. They set a “buy” rating and a $192.00 price objective on the stock. Nine equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $139.88.
Shares of ICPT stock traded down $3.73 during trading hours on Friday, reaching $95.72. 669,200 shares of the company’s stock were exchanged, compared to its average volume of 687,364. The company has a market cap of $3.10 billion, a PE ratio of -6.66 and a beta of -1.94. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 2.48. Intercept Pharmaceuticals has a fifty-two week low of $51.05 and a fifty-two week high of $133.74.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.83) by $0.25. The business had revenue of $43.58 million for the quarter, compared to the consensus estimate of $41.26 million. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The business’s quarterly revenue was up 41.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.46) earnings per share. On average, equities analysts forecast that Intercept Pharmaceuticals will post -10.56 earnings per share for the current year.
In other news, insider David Shapiro sold 759 shares of the business’s stock in a transaction on Friday, October 5th. The shares were sold at an average price of $110.65, for a total transaction of $83,983.35. Following the sale, the insider now directly owns 39,152 shares of the company’s stock, valued at $4,332,168.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 9,101 shares of company stock worth $984,488 over the last three months. Corporate insiders own 4.90% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in Intercept Pharmaceuticals by 17.5% in the second quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after purchasing an additional 661,542 shares during the last quarter. First Trust Advisors LP boosted its holdings in Intercept Pharmaceuticals by 2.7% in the second quarter. First Trust Advisors LP now owns 840,584 shares of the biopharmaceutical company’s stock valued at $70,533,000 after purchasing an additional 22,310 shares during the last quarter. Northern Trust Corp boosted its holdings in Intercept Pharmaceuticals by 190.3% in the second quarter. Northern Trust Corp now owns 257,755 shares of the biopharmaceutical company’s stock valued at $21,629,000 after purchasing an additional 168,955 shares during the last quarter. Millennium Management LLC boosted its holdings in Intercept Pharmaceuticals by 168.9% in the first quarter. Millennium Management LLC now owns 235,180 shares of the biopharmaceutical company’s stock valued at $14,468,000 after purchasing an additional 147,719 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its holdings in Intercept Pharmaceuticals by 31.4% in the second quarter. Peregrine Capital Management LLC now owns 151,434 shares of the biopharmaceutical company’s stock valued at $12,707,000 after purchasing an additional 36,189 shares during the last quarter. 69.38% of the stock is currently owned by institutional investors.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
See Also: Ex-Dividend
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.